Home Proteases Neprilysin inhibitor - Apoptosis related activator - Angiotensin Receptor inhibitor Sacubitril/valsartan (LCZ696) For research use only.

Sacubitril/valsartan (LCZ696)

Synonyms: Sacubitril, Valsartan

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

Sacubitril/valsartan (LCZ696) Chemical Structure

Sacubitril/valsartan (LCZ696) Chemical Structure

CAS: 936623-90-4

Selleck's Sacubitril/valsartan (LCZ696) has been cited by 10 Publications

2 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.99%
99.99

Related compound libraries

Choose Selective Neprilysin Inhibitors

Biological Activity

Description Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Targets
RAAS [1]
In Vivo
In vivo In double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) induces a dose-dependent and long-lasting reduction in mean arterial pressure (MAP), and stimulates a rapid and dose-dependent augmentation of plasma ANP immunoreactivity. [1] In rat myocardial infarction (MI) model, LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. [2]
Animal Research Animal Models Double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity
Dosages ~60 mg/kg
Administration p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02690974 Completed Hearth Failure With Reduced Ejection Fraction (HFrEF) Novartis Pharmaceuticals|Novartis March 8 2016 Phase 4
NCT02661217 Completed Heart Failure With Reduced Ejection Fraction Novartis Pharmaceuticals|Novartis February 12 2016 Phase 4
NCT02226120 Completed Chronic Heart Failure With Reduced Ejection Fraction Novartis Pharmaceuticals|Novartis October 16 2014 Phase 3

Chemical lnformation & Solubility

Molecular Weight 915.98 Formula

C24H29N5O3.C24H29NO5.5/2H2O.3Na
CAS No. 936623-90-4 SDF Download Sacubitril/valsartan (LCZ696) SDF
Smiles [Na+].[Na+].[Na+].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[NH]3)C(C(C)C)C(O)=O.CCOC(=O)C(C)CC(CC4=CC=C(C=C4)C5=CC=CC=C5)NC(=O)CCC(O)=O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 100 mg/mL ( (109.17 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Sacubitril/valsartan (LCZ696) | Sacubitril/valsartan (LCZ696) supplier | purchase Sacubitril/valsartan (LCZ696) | Sacubitril/valsartan (LCZ696) cost | Sacubitril/valsartan (LCZ696) manufacturer | order Sacubitril/valsartan (LCZ696) | Sacubitril/valsartan (LCZ696) distributor